Satellos Bioscience Inc.

Contributing Author

Recent Articles by Satellos Bioscience Inc.

4 hours	Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247 MSLE +12.06% GlobeNewswire
Jun-29	Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy MSLE +11.44% GlobeNewswire
Jun-25	Satellos to Present Clinical Program Updates at ICNMD 2026 MSLE +19.40% GlobeNewswire
Jun-17	Satellos Bioscience Announces Results of Annual Meeting of Shareholders MSLE GlobeNewswire
May-27	Satellos to Participate in Upcoming Investor Conferences MSLE +6.98% GlobeNewswire
May-15	Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress MSLE GlobeNewswire
Apr-09	Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference MSLE GlobeNewswire
Mar-27	Satellos Reports 2025 Financial Results and Highlights Recent Company Progress MSLE -10.68% GlobeNewswire
Mar-10	Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference MSLE -18.11% GlobeNewswire